Saxenda market outlook points to steady growth through 2026

The Saxenda market is projected to keep expanding through 2026 as obesity, diabetes and demand for long-term weight-loss treatments rise globally. North America leads today, while Asia-Pacific is expected to grow fastest as healthcare access and obesity awareness improve.

Why it matters: - Saxenda sits in a growing market tied to two of the biggest chronic disease burdens: obesity and diabetes. - Rising demand for long-term weight-loss care could expand use of injectable GLP-1 therapies and reshape obesity treatment pathways. - The market outlook also signals where healthcare spending, provider attention and patient demand are likely to concentrate next.

What happened: - The Business Research Company released its Saxenda Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Saxenda market is gaining momentum as obesity and related health conditions become more common worldwide. - The report projects continued growth through 2026, driven by demand for long-term weight-loss solutions and broader adoption of injectable treatments. - North America held the largest Saxenda market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Saxenda is a prescription drug containing liraglutide. - Saxenda is formulated to help adults with obesity or overweight manage body weight. - The drug works by mimicking a natural hormone that controls appetite. - Saxenda is intended to be used with a calorie-restricted diet and increased physical activity. - Historical growth in the market was driven by rising obesity rates, greater awareness of weight-related health complications, expansion of specialized obesity clinics, wider physician acceptance of injectable therapies and better insurance reimbursement. - Future growth is expected to come from rising demand for long-term weight-loss solutions, a stronger focus on metabolic health, expansion of digital weight-management platforms, more investment in obesity drug development and improved patient adherence to injectable treatment. - Major trends expected to shape the market include wider use of GLP-1 receptor agonists, stronger preference for pharmacological weight-loss methods, broader use of injectable obesity therapies, more long-term obesity care programs and greater emphasis on appetite regulation treatments. - In England, 64.0% of adults ages 18 and older were classified as overweight or obese from 2022 to 2023, according to the UK’s Office for Health Improvement & Disparities in May 2024. - In Ontario, nearly 30% of the population, or about 2.4 million people, had diabetes or prediabetes in 2023, according to a February 2023 Diabetes Canada report. - The Diabetes Canada report forecasts a 25% increase in prevalence over the next decade, with annual treatment costs rising from $1.7 billion to $2.1 billion by 2033. - The report says 2026 editions now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - The report offers a free sample at the company’s sample request page. - The full report is available here.

Between the lines: - The market story is less about Saxenda alone and more about the broader shift toward chronic, medication-based weight management. - High obesity and diabetes rates strengthen the case for therapies that target appetite, glucose control and sustained weight loss at the same time. - The regional split suggests mature demand in North America and faster adoption potential in markets where healthcare infrastructure is still expanding.

What's next: - The report points to continued competition in injectable obesity therapy as GLP-1 drugs gain wider use. - Growth in digital weight-management tools and long-term obesity care programs could support broader treatment adoption. - The Asia-Pacific region is likely to become a key growth arena as awareness and access improve.

The bottom line: - Saxenda is positioned in a market that is expanding on the back of rising obesity, diabetes and demand for durable weight-loss solutions.